Sven Korte
Covance
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sven Korte.
Journal of Medical Primatology | 2009
Barthel Schmelting; Marc Niehoff; B. Egner; Sven Korte; Gerhard F. Weinbauer
Background Current approaches for accurate blood pressure determination rely predominantly on invasive techniques. High Definition Oscillometry (HDO) was evaluated as a potential non‐invasive approach for accurate blood pressure recordings in cynomolgus monkeys.
Journal of Applied Toxicology | 2014
Eric J. de Waal; Maria Desmidt; Sven Korte; Marc Niehoff; Kevan Chase; Wayne Arrowsmith; Ann Lampo
JNJ‐37822681 is a potent, specific and fast dissociating dopamine D2 receptor antagonist intended for the treatment of schizophrenia. Its nonclinical toxicological profile was investigated in a series of general repeat dose toxicity studies in cynomolgus monkeys and Sprague–Dawley rats. The maximum duration of treatment was 9 and 6 months, respectively. Interspecies differences were noted in the response to JNJ‐37822681 in terms of extrapyramidal (EPS)‐like clinical signs and prolactin‐mediated tissue changes in the mammary gland. Monkeys showed severe EPS‐like clinical signs such as abnormal posture, abnormal eye movements and hallucination‐like behavior at relatively low exposures compared to those associated with EPS in patients with schizophrenia. The high sensitivity of the monkey to JNJ‐37822681‐induced EPS‐like signs was unexpected based on the fast dissociating properties of the compound. Rats, however, were not prone to EPS. Elevated serum prolactin levels were found in rats and monkeys. While rats showed slight to moderate prolactin‐related tissue changes upon histopathological examination in all studies, which among others affected the mammary gland, only minor mammary gland tissue changes were noted in monkeys. Prolactin levels were only slightly increased in patients with schizophrenia receiving relatively high dose levels of JNJ‐37822681. The monkey toxicology studies did not provide an exposure‐based safety margin, while in rats adverse effects were only noted at exposures considerably higher than those achieved at efficacious plasma concentrations in the clinic. Overall, the available data suggest that the cynomolgus monkey showed better predictivity towards the nature of JNJ‐37822681‐associated adverse events in humans than the Sprague–Dawley rat. Copyright
The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment | 2015
Kerstin Mätz-Rensing; Sven Korte
The common marmoset, a unique South American New World monkey species, is widespread in laboratory settings and in zoological gardens. In recent years, common marmosets have become a suitable animal model in many research fields. Their small size, easy handling and husbandry, early sexual maturity, and short gestation makes them attractive for toxicology and reproductive biology. Important distinctions from other primate species regarding nutrition, reproduction, and development exist, and this knowledge is essential for successful husbandry breeding and study design. This chapter provides an overview of important aspects of the basic physiology of the common marmoset.
The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment | 2015
C. Marc Luetjens; J. Kaspareit; Sven Korte; Joachim Wistuba
Abstract In this chapter we review the data available on the use of marmosets as a valuable NHP model and report on histopathological specificities in a variety of organs. Based on the differences described, the marmoset model is discussed in the context of toxicological safety assessments as well as a model for general research on the pathophysiology of human diseases.
Journal of Pharmacological and Toxicological Methods | 2007
Sven Korte; Antje Fuchs; Gerhard F. Weinbauer; Elena Moscardo; Alessandra Giarola
Toxicological Sciences | 2016
Brian R. Vuillemenot; Sven Korte; Teresa Leah Wright; Eric L. Adams; Robert B. Boyd; Mark Butt
Journal of Pharmacological and Toxicological Methods | 2018
Daniela Smieja; Marc Niehoff; Sven Korte
The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment | 2015
Werner Frings; Marc Niehoff; Sven Korte
The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment | 2015
Joerg Bluemel; Sven Korte; Emanuel Schenck; Gerhard F. Weinbauer
Archive | 2015
Joerg Bluemel; Sven Korte; Emanuel Schenck; Gerhard F. Weinbauer